Coherus enters Phase 1b combo trial with Janssen for tagmokitug in mCRPC

Coherus Oncology, Inc.

Clinical supply agreement with Janssen to evaluate tagmokitug (anti-CCR8) plus pasritamig in mCRPC Phase 1b.
Coherus sponsors trial; Janssen supplies pasritamig. Both retain full commercial rights to their compounds.
Tagmokitug is an investigational cytolytic monoclonal antibody targeting CCR8; study to start in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.